Your browser doesn't support javascript.
loading
Clinical utilization of artificial intelligence-based COVID-19 pneumonia quantification using chest computed tomography - a multicenter retrospective cohort study in Japan.
Tanaka, Hiromu; Maetani, Tomoki; Chubachi, Shotaro; Tanabe, Naoya; Shiraishi, Yusuke; Asakura, Takanori; Namkoong, Ho; Shimada, Takashi; Azekawa, Shuhei; Otake, Shiro; Nakagawara, Kensuke; Fukushima, Takahiro; Watase, Mayuko; Terai, Hideki; Sasaki, Mamoru; Ueda, Soichiro; Kato, Yukari; Harada, Norihiro; Suzuki, Shoji; Yoshida, Shuichi; Tateno, Hiroki; Yamada, Yoshitake; Jinzaki, Masahiro; Hirai, Toyohiro; Okada, Yukinori; Koike, Ryuji; Ishii, Makoto; Hasegawa, Naoki; Kimura, Akinori; Imoto, Seiya; Miyano, Satoru; Ogawa, Seishi; Kanai, Takanori; Fukunaga, Koichi.
Afiliação
  • Tanaka H; Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
  • Maetani T; Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
  • Chubachi S; Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. bachibachi472000@z6.keio.jp.
  • Tanabe N; Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan. ntana@kuhp.kyoto-u.ac.jp.
  • Shiraishi Y; Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
  • Asakura T; Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
  • Namkoong H; Department of Clinical Medicine (Laboratory of Bioregulatory Medicine), Kitasato University School of Pharmacy, Tokyo, Japan.
  • Shimada T; Department of Respiratory Medicine, Kitasato University, Kitasato Institute Hospital, Tokyo, Japan.
  • Azekawa S; Department of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan.
  • Otake S; Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
  • Nakagawara K; Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
  • Fukushima T; Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
  • Watase M; Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
  • Terai H; Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
  • Sasaki M; Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
  • Ueda S; Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
  • Kato Y; Department of Respiratory Medicine, JCHO (Japan Community Health care Organization), Saitama Medical Center, Saitama, Japan.
  • Harada N; Department of Respiratory Medicine, JCHO (Japan Community Health care Organization), Saitama Medical Center, Saitama, Japan.
  • Suzuki S; Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, Japan.
  • Yoshida S; Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, Japan.
  • Tateno H; Department of Pulmonary Medicine, Saitama City Hospital, Saitama, Japan.
  • Yamada Y; Department of Pulmonary Medicine, Saitama City Hospital, Saitama, Japan.
  • Jinzaki M; Department of Pulmonary Medicine, Saitama City Hospital, Saitama, Japan.
  • Hirai T; Department of Radiology, Keio University School of Medicine, Tokyo, Japan.
  • Okada Y; Department of Radiology, Keio University School of Medicine, Tokyo, Japan.
  • Koike R; Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
  • Ishii M; Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, Japan.
  • Hasegawa N; Department of Genome Informatics, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan.
  • Kimura A; Laboratory for Systems Genetics, RIKEN Center for Integrative Medical Sciences, Kanagawa, Japan.
  • Imoto S; Health Science Research and Development Center (HeRD), Tokyo Medical and Dental University, Tokyo, Japan.
  • Miyano S; Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
  • Ogawa S; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Kanai T; Department of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan.
  • Fukunaga K; Institute of Research, Tokyo Medical and Dental University, Tokyo, Japan.
Respir Res ; 24(1): 241, 2023 Oct 05.
Article em En | MEDLINE | ID: mdl-37798709
BACKGROUND: Computed tomography (CT) imaging and artificial intelligence (AI)-based analyses have aided in the diagnosis and prediction of the severity of COVID-19. However, the potential of AI-based CT quantification of pneumonia in assessing patients with COVID-19 has not yet been fully explored. This study aimed to investigate the potential of AI-based CT quantification of COVID-19 pneumonia to predict the critical outcomes and clinical characteristics of patients with residual lung lesions. METHODS: This retrospective cohort study included 1,200 hospitalized patients with COVID-19 from four hospitals. The incidence of critical outcomes (requiring the support of high-flow oxygen or invasive mechanical ventilation or death) and complications during hospitalization (bacterial infection, renal failure, heart failure, thromboembolism, and liver dysfunction) was compared between the groups of pneumonia with high/low-percentage lung lesions, based on AI-based CT quantification. Additionally, 198 patients underwent CT scans 3 months after admission to analyze prognostic factors for residual lung lesions. RESULTS: The pneumonia group with a high percentage of lung lesions (N = 400) had a higher incidence of critical outcomes and complications during hospitalization than the low percentage group (N = 800). Multivariable analysis demonstrated that AI-based CT quantification of pneumonia was independently associated with critical outcomes (adjusted odds ratio [aOR] 10.5, 95% confidence interval [CI] 5.59-19.7), as well as with oxygen requirement (aOR 6.35, 95% CI 4.60-8.76), IMV requirement (aOR 7.73, 95% CI 2.52-23.7), and mortality rate (aOR 6.46, 95% CI 1.87-22.3). Among patients with follow-up CT scans (N = 198), the multivariable analysis revealed that the pneumonia group with a high percentage of lung lesions on admission (aOR 4.74, 95% CI 2.36-9.52), older age (aOR 2.53, 95% CI 1.16-5.51), female sex (aOR 2.41, 95% CI 1.13-5.11), and medical history of hypertension (aOR 2.22, 95% CI 1.09-4.50) independently predicted persistent residual lung lesions. CONCLUSIONS: AI-based CT quantification of pneumonia provides valuable information beyond qualitative evaluation by physicians, enabling the prediction of critical outcomes and residual lung lesions in patients with COVID-19.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pneumonia / COVID-19 Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pneumonia / COVID-19 Idioma: En Ano de publicação: 2023 Tipo de documento: Article